Genelux Co. (NASDAQ:GNLX - Free Report) - Investment analysts at Brookline Capital Management issued their FY2024 EPS estimates for shares of Genelux in a research report issued to clients and investors on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings per share of ($0.89) for the year. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux's Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.70) EPS.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $18.25.
Get Our Latest Analysis on Genelux
Genelux Stock Down 3.0 %
Shares of NASDAQ:GNLX traded down $0.08 during midday trading on Friday, hitting $2.62. 123,726 shares of the stock traded hands, compared to its average volume of 205,776. The business's 50 day moving average is $4.06 and its two-hundred day moving average is $3.10. The stock has a market capitalization of $90.99 million, a PE ratio of -2.78 and a beta of -1.41. Genelux has a one year low of $1.60 and a one year high of $6.50.
Genelux (NASDAQ:GNLX - Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09).
Hedge Funds Weigh In On Genelux
A number of hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC boosted its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after buying an additional 2,857 shares during the last quarter. LifeSteps Financial Inc. boosted its stake in shares of Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after acquiring an additional 8,715 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Genelux by 76.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company's stock valued at $50,000 after acquiring an additional 9,114 shares during the period. Virtu Financial LLC purchased a new stake in shares of Genelux in the 4th quarter worth $25,000. Finally, Raymond James Financial Inc. bought a new position in Genelux in the 4th quarter worth $41,000. Hedge funds and other institutional investors own 37.33% of the company's stock.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
